Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy
Rhea-AI Summary
Calidi Biotherapeutics (NYSE American: CLDI) will present data at the Internation Oncolytic Virus Conference in Reykjavík on April 28, 2026 highlighting its RedTail platform and lead candidate CLD-401. The presentation will describe systemic delivery, tumor-selective replication, immune-evasion features, and high local expression of therapeutic payloads in preclinical models.
The company expects to file an IND for CLD-401 by the end of 2026 and is developing CLD-501 to express a TROP2-targeting TCE plus IL-15SA in the tumor microenvironment while pursuing strategic partnerships.
Positive
- None.
Negative
- None.
News Market Reaction – CLDI
In the Apr 14 session, CLDI declined 4.40%, reflecting a moderate negative market reaction. Argus tracked a peak move of +8.1% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.5x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Conference presentation | Positive | -1.3% | ASGCT talk on RedTail platform and CLD-401 preclinical data. |
| Apr 02 | Conference data update | Positive | -2.7% | AACR presentation of CLD-401 IL-15 SA tumor-restricted expression data. |
| Apr 01 | Pipeline platform data | Positive | +1.6% | AACR data on in situ T-cell engagers and TROP2-targeting candidate. |
| Mar 27 | Earnings and funding | Negative | -11.7% | Q4/FY25 results with $25.6M net loss and $6.5M capital raised. |
| Mar 24 | Clinical partnership | Positive | -3.6% | Avance Clinical partnership to accelerate Australian approval and Phase I trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive R&D and partnership news has often coincided with negative next-day moves, while the larger earnings-related loss drew a sharper selloff.
Over the last month, Calidi has repeatedly highlighted its RedTail platform and lead asset CLD-401 at major meetings (AACR, ASGCT) and through partnership news, consistently guiding to an IND by end of 2026. Despite this, several such announcements on 04/02, 04/07, and the Avance partnership on 03/24 saw negative 24-hour price reactions. The 03/27 earnings release, noting a $25.6M 2025 net loss and financing, drew the steepest decline.
Key Terms
virotherapy medical
tumor microenvironment medical
extracellular enveloped medical
t-cell engagers medical
il-15 superagonist medical
nk-cell medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present at the Internation Oncolytic Virus Conference (IOVC) in Reykjavik, Iceland on April 28th, 2026. The Company will present data on its RedTail platform and its lead compound CLD-401.
RedTail is Calidi’s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly at the tumor site while limiting peripheral exposure. Data presented at IOVC by Duong Nguyen, PhD, Senior Director, Translational Research and Innovation for Calidi, will showcase the ability of the RedTail extracellular enveloped and CD55-overexpressing virus (EEV) to avoid immune clearance, replicate only in target cells, and deliver high concentrations of genetic medicine to sites of disease.
CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL-15 superagonist (IL-15 SA), a known T and NK-cell activator, in the TME. The Company expects to file an IND for CLD-401 by the end of 2026. Additionally, Calidi is expanding the RedTail platform to enable in situ expression of T-cell engagers (TCEs) in solid tumors, including in combination with T-cell activating payloads such as IL15 SA. This strategy is intended to support localized T-cell engagement within the TME following systemic administration. The Company is developing CLD-501, a RedTail virus that expresses high levels of a TROP2-targeting TCE and IL-15SA in the TME.
“The data we will present at IOVC highlight the advances we have made with our novel approach to the targeted, systemic delivery of genetic medicines” said Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations of Calidi. “In our preclinical and syngeneic models, we are seeing profound biology driven by targeted genetic expression with RedTail candidates.”
“We continue to advance the RedTail platform with an IND filing expected this year for CLD-401” said Eric Poma, PhD, Chief Executive Officer of Calidi. “We continue to expand what the RedTail platform can do with new payload, a novel approach to in situ T-cell engagers, and ongoing lead discovery in indications outside of oncology.”
The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.
About Calidi
Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.
Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For Investors:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
